Generic Name and Formulations:
Bimatoprost 0.03%; oph soln; contains benzalkonium chloride.
Indications for LATISSE:
Hypotrichosis of the eyelashes.
1 drop once nightly; apply evenly along upper eyelid skin margin at the base of eyelashes. Repeat for opposite eyelid margin with new sterile applicator. Blot any excess solution runoff.
Do not apply to lower eyelash line. Repeated contact with bimatoprost outside the treatment area may cause hair growth. Ocular hypertension; monitor for changes to intraocular pressure. Ocular inflammation (eg, uveitis). Aphakia. Pseudophakia with torn posterior lens capsule. Risk of macular edema. Contact lenses (remove; may reinsert lenses 15 minutes after administration). Pregnancy (Cat.C). Nursing mothers.
Concomitant with other intraocular pressure (IOP)-lowering prostaglandin analogues may decrease IOP-lowering effects.
Eye pruritus, conjunctival hyperemia, increased ocular pigmentation (iris, eyelid; may be permanent), ocular irritation, dry eye, erythema of the eyelid, macular edema, abnormal hair growth.
Soln—3mL (w. disposable sterile applicators)
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Risk for Cardiovascular Disease Higher in Survivors of Testicular Cancer
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|